tbuckley/cabot-search huggingface dataset:
2016 ACC/ASE/ASNC/HRS/SCAI Health Policy Statement on Integrating the Healthcare Enterprise
Authors: John R. Windle, Alan S. Katz, J. Paul Dow, Edward T.A. Fry, Andrew M. Keller, Terran Lamp, Alexander Lippitt, Marianne P. Paruche, Frederic S. Resnic, Gerald A. Serwer, David J. Slotwiner, James E. Tcheng, Peter L. Tilkemeier, Bonnie H. Weiner, William S. Weintraub
Journal: Journal of the American College of Cardiology (2016)

Richard J. Kovacs, MD, FACC, Chair 

Deepak Bhatt, MD, FACC

Ralph Brindis, MD, MPH, MACC

Paul N. Casale, MD, MPH, FACC

Edward T.A. Fry, MD, FACC

Paul A. Heidenreich, MD, FACC

Jeffrey P. Jacobs, MD, FACC

James L. Januzzi, Jr, MD, FACC

Amy L. Miller, MD, PhD, FACC

Athena Poppas, MD, FACC
Elevated Levels of IL-17, MIP-1 β, MIG and ITAC in B-Cell Chronic Lymphocytic Leukemia: Correlation with Prognostic Markers.
Authors: Xiao J. Yan, Michael Centola, Igor Dozmorov, Rajendra N. Damle, Steven L. Allen, Kanti R. Rai, BArbara Sherry, Nicholas Chiorazzi
Journal: Blood (2006)
Mexico's path towards the Sustainable Development Goal for health: an assessment of the feasibility of reducing premature mortality by 40% by 2030
Authors: Eduardo González-Pier, Mariana Barraza-Lloréns, Naomi Beyeler, Dean Jamison, Felicia Knaul, Rafael Lozano, Gavin Yamey, Jaime Sepúlveda
Journal: The Lancet Global Health (2016)

The United Nations Sustainable Development Goal for health (SDG3) poses complex challenges for signatory countries that will require clear roadmaps to set priorities over the next 15 years. Building upon the work of the Commission on Investing in Health and published estimates of feasible global mortality SDG3 targets, we analysed Mexico's mortality to assess the feasibility of reducing premature (0-69 years) mortality and propose a path to meet SDG3.We developed a baseline scenario applying 2010 age-specific and cause-specific mortality rates from the Mexican National Institute of Statistics and Geography (INEGI) to the 2030 UN Population Division (UNPD) population projections. In a second scenario, INEGI age-specific and cause-specific trends in death rates from 2000 to 2014 were projected to 2030 and adjusted to match the UNPD 2030 mortality projections. A third scenario assumed a 40% reduction in premature deaths across all ages and causes. By comparing these scenarios we quantified shortfalls in mortality reductions by age group and cause, and forecasted life expectancy pathways for Mexico to converge to better performing countries.UNPD-projected death rates yield a 25·9% reduction of premature mortality for Mexico. Accelerated reductions in adult mortality are necessary to reach a 40% reduction by 2030. Mortality declines aggregated across all age groups mask uneven gains across health disorders. Injuries, particularly road traffic accidents and homicides, are the main health challenge for young adults (aged 20-49 years) whereas unabated diabetes mortality is the single most important health concern for older adults (aged 50-69 years).Urgent action is now required to control non-communicable diseases and reduce fatal injuries in Mexico, making a 40% reduction in premature mortality by 2030 feasible and putting Mexico back on a track of substantial life expectancy convergence with better performing countries. Our study provides a roadmap for setting national health priorities. Further analysis of the equity implications of following the suggested pathway remains a subject of future research.Mexico's Ministry of Health, University of California, San Francisco, and Bill & Melinda Gates Foundation.
Error in medicine
Authors: M. Guarnieri
Journal: JAMA (1995)

To the Editor.  —Dr Leape's 1 article on error in medicine offers a thoughtful and timely comment on a critical problem in health care. Unfortunately, one of the prescriptions may be dangerous medicine: the recommendation to simplify tasks to reduce errors.  At first glance, the recommendation appears attractive. Some businesses have already adopted the practice of dumbing  jobs. Instead of training workers, the idea is to make the work so simple that people do not have to read, write, add, or even think. For example, to dumb down a dispensary, install electronic scanners. Dumb down fast-food jobs with pictures on cash register keys instead of numbers. Dumb down jobs in the billing office by imposing standard protocols so rigid that little independent judgment is required or even allowed. Dumbing-down employers opt out of investing in the workforce. They view training people as too expensive. Employers even have dumbed down
Brief Report: Whole‐Exome Sequencing for Identification of Potential Causal Variants for Diffuse Cutaneous Systemic Sclerosis
Authors: Angel C. Y. Mak, Paul L. F. Tang, Clare Cleveland, Melanie H. Smith, M. Kari Connolly, Tamiko R. Katsumoto, Paul J. Wolters, Pui‐Yan Kwok, Lindsey A. Criswell
Journal: Arthritis & Rheumatology (2016)

Scleroderma is a genetically complex autoimmune disease with substantial phenotypic heterogeneity. Previous genome-wide association studies have identified common genetic variants associated with disease risk, but these studies are not designed to capture rare or potential causal variants. Our goal was to identify rare as well as common genetic variants in patients with diffuse cutaneous systemic sclerosis (dcSSc) through whole-exome sequencing (WES) in order to identify potential causal variants.We generated WES data for 32 dcSSc patients with or without interstitial lung disease (ILD) and for 17 healthy "in-house" controls. Variants were annotated and filtered by quality, minor allele frequency, and deleterious effects on gene function. We applied a gene burden test to identify novel dcSSc and dcSSc-associated ILD candidate genes that were enriched with deleterious variants in cases compared to in-house controls as well as controls from the 1000 Genomes Project (n = 130).We identified 70 genes that were enriched with deleterious variants in dcSSc patients. Two of them (BANK1 and TERT) were in pathways previously implicated in SSc or ILD pathogenesis or known susceptibility loci. Newly identified genes (COL4A3, COL4A4, COL5A2, COL13A1, and COL22A1) were significantly enriched in the extracellular matrix-related pathway, which is relevant to the fibrotic features of dcSSc, and in the DNA repair pathway (XRCC4).This study demonstrates the value of WES for the identification of novel gene variants and pathways that may contribute to scleroderma risk and/or severity. The candidate genes we discovered are potential targets for in-depth functional studies.
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
Authors: Matteo G. Della Porta, Anna Gallì, Andrea Bacigalupo, Silvia Zibellini, Massimo Bernardi, Ettore Rizzo, Bernardino Allione, Maria Teresa van Lint, Pietro Pioltelli, Paola Marenco, Alberto Bosi, Maria Teresa Voso, Simona Sica, Mariella Cuzzola, Emanuele Angelucci, Marianna Rossi, Marta Ubezio, Alberto Malovini, Ivan Limongelli, Virginia V. Ferretti, Orietta Spinelli, Cristina Tresoldi, Sarah Pozzi, Silvia Luchetti, Laura Pezzetti, Silvia Catricalà, Chiara Milanesi, Alberto Riva, Benedetto Bruno, Fabio Ciceri, Francesca Bonifazi, Riccardo Bellazzi, Elli Papaemmanuil, Armando Santoro, Emilio P. Alessandrino, Alessandro Rambaldi, Mario Cazzola
Journal: Journal of Clinical Oncology (2016)

The genetic basis of myelodysplastic syndromes (MDS) is heterogeneous, and various combinations of somatic mutations are associated with different clinical phenotypes and outcomes. Whether the genetic basis of MDS influences the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT) is unclear.We studied 401 patients with MDS or acute myeloid leukemia (AML) evolving from MDS (MDS/AML). We used massively parallel sequencing to examine tumor samples collected before HSCT for somatic mutations in 34 recurrently mutated genes in myeloid neoplasms. We then analyzed the impact of mutations on the outcome of HSCT.Overall, 87% of patients carried one or more oncogenic mutations. Somatic mutations of ASXL1, RUNX1, and TP53 were independent predictors of relapse and overall survival after HSCT in both patients with MDS and patients with MDS/AML (P values ranging from .003 to .035). In patients with MDS/AML, gene ontology (ie, secondary-type AML carrying mutations in genes of RNA splicing machinery, TP53-mutated AML, or de novo AML) was an independent predictor of posttransplantation outcome (P = .013). The impact of ASXL1, RUNX1, and TP53 mutations on posttransplantation survival was independent of the revised International Prognostic Scoring System (IPSS-R). Combining somatic mutations and IPSS-R risk improved the ability to stratify patients by capturing more prognostic information at an individual level. Accounting for various combinations of IPSS-R risk and somatic mutations, the 5-year probability of survival after HSCT ranged from 0% to 73%.Somatic mutation in ASXL1, RUNX1, or TP53 is independently associated with unfavorable outcomes and shorter survival after allogeneic HSCT for patients with MDS and MDS/AML. Accounting for these genetic lesions may improve the prognostication precision in clinical practice and in designing clinical trials.
Integrative Analysis Of mRNA/miRNA Expression Profiles Identified JARID2 As a Shared Target Of Deregulated Mirnas In Primary Myelofibrosis
Authors: Roberta Zini, Ruggiero Norfo, Valentina Pennucci, Elisa Bianchi, Simona Salati, Paola Guglielmelli, Andrea Bisognin, Vittorio Rosti, Daniela Pietra, Silvia Salmoiraghi, Costanza Bogani, Tiziana Fanelli, Samantha Ruberti, Giorgia Sacchi, Zelia Prudente, Giovanni Barosi, Mario Cazzola, Alessandro Rambaldi, Stefania Bortoluzzi, Sergio Ferrari, Enrico Tagliafico, Alessandro M Vannucchi, Rossella Manfredini
Journal: Blood (2013)
Chronic electronic cigarette exposure in mice induces features of COPD in a nicotine-dependent manner
Authors: Itsaso Garcia-Arcos, Patrick Geraghty, Nathalie Baumlin, Michael Campos, Abdoulaye Jules Dabo, Bakr Jundi, Neville Cummins, Edward Eden, Astrid Grosche, Matthias Salathe, Robert Foronjy
Journal: Thorax (2016)

<h3>Background</h3> The use of electronic (e)-cigarettes is increasing rapidly, but their lung health effects are not established. Clinical studies examining the potential long-term impact of e-cigarette use on lung health will take decades. To address this gap in knowledge, this study investigated the effects of exposure to aerosolised nicotine-free and nicotine-containing e-cigarette fluid on mouse lungs and normal human airway epithelial cells. <h3>Methods</h3> Mice were exposed to aerosolised phosphate-buffered saline, nicotine-free or nicotine-containing e-cigarette solution, 1-hour daily for 4 months. Normal human bronchial epithelial (NHBE) cells cultured at an air-liquid interface were exposed to e-cigarette vapours or nicotine solutions using a Vitrocell smoke exposure robot. <h3>Results</h3> Inhalation of nicotine-containing e-cigarettes increased airway hyper-reactivity, distal airspace enlargement, mucin production, cytokine and protease expression. Exposure to nicotine-free e-cigarettes did not affect these lung parameters. NHBE cells exposed to nicotine-containing e-cigarette vapour showed impaired ciliary beat frequency, airway surface liquid volume, cystic fibrosis transmembrane regulator and ATP-stimulated K+ ion conductance and decreased expression of FOXJ1 and KCNMA1. Exposure of NHBE cells to nicotine for 5 days increased interleukin (IL)-6 and IL-8 secretion. <h3>Conclusions</h3> Exposure to inhaled nicotine-containing e-cigarette fluids triggered effects normally associated with the development of COPD including cytokine expression, airway hyper-reactivity and lung tissue destruction. These effects were nicotine-dependent both in the mouse lung and in human airway cells, suggesting that inhaled nicotine contributes to airway and lung disease in addition to its addictive properties. Thus, these findings highlight the potential dangers of nicotine inhalation during e-cigarette use.
Retail Stores and the Fight Against Tobacco—Following the Money
Authors: Cheryl Bettigole, Thomas A. Farley
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The clinical relevance of birch pollen profilin cross-reactivity in sensitized patients
Authors: F. Wölbing, J. Kunz, W. E. Kempf, C. Grimmel, J. Fischer, T. Biedermann
Journal: Allergy (2016)

Overlapping seasons and cross-reactivity, especially to grass pollen profilin, can hamper the diagnosis of birch pollen allergy. To identify the primary sensitizing allergen and the clinical relevance of cross-sensitization, we correlated sensitization profiles with in vitro and in vivo tests, symptom scores, and pollen counts.A total of 433 patients with positive skin prick test (SPT) to birch pollen were analyzed regarding IgE to major birch and grass pollen allergens Bet v 1 and Phl p 1/p 5 and the profilins Bet v 2 and Phl p 12. Subgroups were analyzed by basophil activation test (BAT) and CAP-FEIA-based cross- and self-inhibition tests.A total of 349 patients were sensitized to Bet v 1, 44 patients to both Bet v 1 and Bet v 2, and 15 patients to Bet v 2 only. From Bet v 2-sensitized patients, 40 were also sensitized to Phl p 12. Ex vivo, Bet v 2 and Phl p 12 induced dose-dependent activation in basophils of these patients. Cross- and self-inhibition tests with both allergens confirmed cross-reactivity. However, semiquantitative analysis of SPTs demonstrated markedly increased reactivity to grass compared to birch pollen extract in Bet v 2 only sensitized patients. Accordingly, in most of those patients, clinical symptoms precisely correlated with grass pollen counts.Identification of the clinically relevant and sensitizing allergen needs correlation of actual pollen counts with clinical symptoms and sensitization status to major allergens. Semiquantitative analysis of SPT or BAT and determining profilin-specific IgE can contribute to making the diagnosis.
A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
Authors: Gerhardt Attard, Axel S. Merseburger, Cora N. Sternberg, Linda Cerbone, Federica Recine, Robert J. Jones, Susan Feyerabend, Alfredo Berruti, Steven Joniau, Peter Schatteman, Lajos Geczi, Peter Tenke, Patrick Werbrouck, Florence Lefresne, Florence Nave Shelby, Marjolein Lahaye, Corinna Pick, Bertrand F. Tombal
Journal: Journal of Clinical Oncology (2016)

261 Background: AA is approved for mCRPC, coadministered with prednisone (P) (5 mg BID) to prevent adverse events (AEs) associated with mineralocorticoid excess (ME). Lower GC doses had not previously been formally evaluated in combination with AA. Methods: This was an open-label, multicenter, phase 2 trial (NCT01867710) of asymptomatic chemotherapy-naïve mCRPC pts randomized 1:1:1:1 to AA (1000 mg QD) plus P 5 mg BID or P 5 mg QD or P 2.5 mg BID or dexamethasone (DEX) 0.5 mg QD. Pts who had previously received GC or ketoconazole were excluded. The primary end point was no ME (% of pts experiencing neither hypokalemia nor hypertension during the first 24 weeks of treatment).Secondary end points included additional safety, as well as response rate in the first 24 weeks, defined as a decline in prostate-specific antigen (PSA) ≥ 50% confirmed after 4 weeks. Results: 164 pts were randomized; 133 (81.6%) completed 24 weeks’ treatment. Median age: 70 years. Table 1 shows the rates of ME, hypertension, hypokalemia and PSA response. Changes in HbA1c values were minimal and observed in 16 (10.7%) pts. Conclusions: These data suggest that P 5 mg BID, which is approved in combination with AA, and DEX 0.5 mg QD, are effective in preventing ME-associated AEs, and that P 2.5 mg BID and P 5 mg QD can be safely used with appropriate monitoring. The suggestion of a higher PSA response rate with DEX 0.5 mg QD arm warrants further validation. Clinical trial information: NCT01867710. [Table: see text]
Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS
Authors: Carlos H. Martinez, Alejandro A. Diaz, Catherine Meldrum, Jeffrey L. Curtis, Christopher B. Cooper, Cheryl Pirozzi, Richard E. Kanner, Robert Paine, Prescott G. Woodruff, Eugene R. Bleecker, Nadia N. Hansel, R. Graham Barr, Nathaniel Marchetti, Gerard J. Criner, Ella A. Kazerooni, Eric A. Hoffman, Brian D. Ross, Craig J. Galban, Christine T. Cigolle, Fernando J. Martinez, MeiLan K. Han
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Aging is associated with reduced FEV
A comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients.
Authors: K. Van Loon, D. Wigler, D. Niedzwiecki, D. Hollis, A. P. Venook, C. D. Blanke, L. Saltz, R. M. Goldberg, C. S. Fuchs, J. A. Meyerhardt
Journal: Journal of Clinical Oncology (2011)

e14026 Background: Patients with colorectal cancer are often highly motivated to seek information about lifestyle and dietary changes which may optimize outcomes. Using data from two large National Cancer Institute-sponsored clinical trials, we compared the dietary and lifestyle practices of patients receiving chemotherapy for stage III colon cancer and metastatic colorectal cancer. Methods: Self-administered questionnaires were completed by patients with stage III colon cancer enrolled in CALGB 89803 (n=1095) and by patients with metastatic colorectal cancer enrolled in CALGB 80405 (n=875), while they were undergoing chemotherapy. Descriptive statistical analyses were performed to evaluate body mass index (BMI), dietary patterns, physical activity, alcohol consumption, cigarette smoking, vitamin and supplement use, and aspirin use in each cohort. Results: Median BMI was comparable for patients with stage III disease and patients with metastatic disease (27.3 vs. 26.5 kg/m2). Stage III patients reported a slightly higher total median MET-hours per week than patients with metastatic disease (4.6 vs. 3.4). 10% of patients with stage III disease and 9% of patients with metastatic disease reported ongoing cigarette use. 47% of patients with stage III disease and 43% of patients with metastatic disease reported abstinence from alcohol. Dietary patterns for both groups were comparable; however, patients with metastatic disease consumed fewer servings per week of many food groups. The vast majority of stage III and metastatic patients failed to meet recommended daily intake of vegetables, fruits, and dairy products. Stage III patients took an average of 1.5 vitamins daily, and patients with metastatic disese took an average of 1.1 vitamins daily. Conclusions: We observed remarkable similarities in dietary patterns and lifestyle behaviors between two large cohorts of stage III colon cancer patients and metastatic colorectal cancer patients actively receiving chemotherapy in the context of a clinical trial. Future research should aim to elucidate the effect of these behavioral factors on patient outcomes.
Solid stress and elastic energy as measures of tumour mechanopathology
Authors: Hadi T. Nia, Hao Liu, Giorgio Seano, Meenal Datta, Dennis Jones, Nuh Rahbari, Joao Incio, Vikash P. Chauhan, Keehoon Jung, John D. Martin, Vasileios Askoxylakis, Timothy P. Padera, Dai Fukumura, Yves Boucher, Francis J. Hornicek, Alan J. Grodzinsky, James W. Baish, Lance L. Munn, Rakesh K. Jain
Journal: Nature Biomedical Engineering (2016)
Antiviral Therapy and Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence
Authors: Yi-Chun Yeh, Pei-Jer Chen, Mei-Shu Lai
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P0712 : The pharmacokinetics of GS-5816, a pangenotypic HCV-specific NS5A inhibitor, in HCV-uninfected subjects with severe renal impairment
Authors: E. Mogalian, A. Mathias, D. Brainard, G. Shen, J. McNally, K. Sajwani, R. Robson, D. Ries, K. Lasseter, T. Marbury
Journal: Journal of Hepatology (2015)
Non–Prostate-Specific Membrane Antigen-Avid Metastatic Lung Nodule From Primary Prostatic Adenocarcinoma
Authors: Deepa Shetty, Han Loh, Chuong Bui, Robert Mansberg, Amirazin Hadjashrafi, Viet Do
Journal: Clinical Nuclear Medicine (2016)

Ga-prostate-specific membrane antigen (PSMA) PET/CT is increasingly used to evaluate recurrent prostatic malignancy due to its high specificity. A 56-year-old man with previous history of treated prostate cancer 4 years earlier presented with rising prostate-specific antigen level and underwent Ga-PSMA PET/CT, which demonstrated an enlarging pulmonary nodule without PSMA avidity. The pulmonary nodule, however, showed moderate uptake on a corresponding FDG PET/CT study, suspicious of primary lung malignancy. Cytological and histopathological examination of the pulmonary nodule confirmed a metastatic deposit from ductal prostatic adenocarcinoma, an uncommon variant of prostatic malignancy.
Tim-3, a Novel Immune Receptor, Is Constitutively Expressed on Human Natural Killer Cells and Functions as An Activating Coreceptor
Authors: Michelle Gleason, Todd Lenvik, Valarie McCullar, Sarah Cooley, Michael Verneris, Toshiro Niki, Mitsuomi Hirashima, Bruce R. Blazar, Jeffrey S. Miller
Journal: Blood (2010)
Comorbidity Measures In Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (HCT)
Authors: Robert Quan Le, Natasha A Jain, Xin Tian, Sawa Ito, Kit Lu, Janice Haggerty, Debbie A Draper, Kamna Chawla, A. John Barrett, Minoo Battiwalla
Journal: Blood (2013)